Antiangiogenic scheduling of lower dose cancer chemotherapy

Cancer Journal

Volumn 7, Issue 5, 2001, Pages 427-436

  Gately, Stephen ^a,b   Kerbel, Robert ^a,c  

^a Northwestern University Medical School ^*

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Antineoplastic agents; Combination therapy; Drug dose and administration schedule; Drug resistance; Neoplasms

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ANTIINFECTIVE AGENT; AUROTHIOMALATE; CAPECITABINE; CAPTOPRIL; CELECOXIB; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IDARUBICIN; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PENICILLAMINE; PIOGLITAZONE; ROSIGLITAZONE; TAMOXIFEN; TEGAFUR; THALIDOMIDE; TIOGUANINE; UNINDEXED DRUG; URACIL; VINBLASTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; DRUG TOLERABILITY; GENETICS; HUMAN; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY; TUMOR CELL; TUMOR VASCULARIZATION; ANIMAL; FORECASTING; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FORECASTING; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0035461919     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. Skipper HE, Schabel FM Jr, Mellett LB et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54:431-450.
2. Schabel FM, Griswold DP, Corbett TH. Testing therapeutic hypotheses in mice and man: Observations on the therapeutic activity against solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors in man. In: DeVita VT, Busch H, eds. Methods in Cancer Research: Cancer Drug Development, Part B. New York: Academic Press Inc., 1979:4-52.
3. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anti-cancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1.
4. Kamen BA, Rubin E, Aisner J et al. High-time chemotherapy or high time for low dose. J Clin Oncol 2000;18:2935-2937.
5. DeVita VT. Cell kinetics and the chemotherapy of cancer. Cancer Chemother Rep 1971;3:2323.
6. Chu E, DeVita VT. Principles of Cancer Management: Chemotherapy. In: Hellman S, DeVita VT, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology (6th ed). Philadelphia: Lippincott Williams & Wilkins, 2001:289-306.
7. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
8. Pecora AL. Progress in clinical application of use of progenitor cells expanded with hematopoietic growth factors. Curr Opin Hematol 2001;8:142-148.
9. Koc ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
10. Weaver C, Schulman K, Buckner C. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001;27(Suppl 2):S23-S29.
11. Sampson FC, Beard SM, Scott F et al. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br J Haematol 2001;113:1015-1019.
12. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;27:1037-1043.
13. Mink SA, Armitage JO. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist 2001;6:247-256.
14. Johnson DH, Carbone DP. Increased dose-intensity in small-cell lung cancer: a failed strategy? J Clin Oncol 1999;17:2297-2299.
15. Weiss RB, Gill GG, Hudis CA. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol 2001;19:2771-2777.
16. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000;342:1069-1076.
17. MacNeil M, Eisenhauer EA. High-dose chemotherapy: is it standard management for any common solid tumor? Ann Oncol 1999;10:1145-1161.
18. Stoler DL, Chen N, Basik M et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 1999;96:15121-15126.
19. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984;44:3643-3653.
20. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-5101.
21. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to ST1-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 (in press).
22. Advani R, Fisher GA, Lum BL et al. A phase I trial of doxorubicin, paclitaxel, and valspodar (psc 833), a modulator of multidrug resistance. Clin Cancer Res 2001;7:1221-1229.
23. Lum BL, Kaubisch S, Fisher GA et al. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDRl gene) mediated drug resistance. Cancer Chemother Pharmacol 2000;45:305-311.
24. Sikic BI. New approaches in cancer treatment. Ann Oncol 1999;10(Suppl 6):149-153.
25. Sikic BI. Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology 1999;13:183-187.
26. Kuttesch JF, Parham DM, Luo X et al. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 1996;14:886-900.
27. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31-36.
28. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
29. Kaban LB, Mulliken JB, Ezekowitz RA et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999;103:1145-1149.
30. Ricketts RR, Hatley RM, Corden BJ et al. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 1994;219:605-612.
31. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-1463.
32. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-282.
33. Folkman J, Hahnfeldt P, Hlatky L. The logic of anti-angiogenic gene therapy. In: Friedmann T, ed. The Development of Gene Therapy. New York: Cold Spring Harbor Laboratory Press, 1998:527-543.
34. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206.
35. Monestiroli S, Mancuso P, Burlini A et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4344.
36. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-228.
37. Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
38. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24.
39. Vacca A, Iurlaro M, Ribatti D et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-4155.
40. McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 1999;5:2669-2671.
41. Relling MV, Hancock ML, Boyett JM et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93:2817-2823.
42. Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet 1991;338:1315-1318.
43. Crist WM, Anderson JR, Meza JL et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-3102.
44. Pazdur R, Lassere Y, Rhodes V et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-2300.
45. Engelsman E, Klijn JC, Rubens RD et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase 111 Trial (10808). Eur J Cancer 1991;27:966-970.
46. Ajani JA, Dumas P. Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol 1992;19:45-47.
47. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am 1999;5:112-114.
48. Ashley DM, Meier L, Kerby T et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996;14:1922-1927.
49. de Jong RS, Hofstra LS, Willemse PH et al. Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1997;66:197-201.
50. de Jong RS, Mulder NH, Dijksterhuis D et al. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res 1995;15:2319-2330.
51. DeVore R, Hainsworth J, Greco FA et al. Chronic oral etoposide in the treatment of lung cancer. Semin Oncol 1992;19:28-35.
52. Doll DC, Sun PC, List AF. Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis. Leuk Res 1994;18:381-384.
53. Doll DC, Kasper LM, Taetle R et al. Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. Leuk Res 1998;22:7-12.
54. Greco FA, Johnson DH, Hainsworth JD. Chronic daily administration of oral etoposide. Semin Oncol 1990;17:71-74.
55. Greco FA, Johnson DH, Hainsworth JD. Chronic oral etoposide. Cancer 1991;67:303-309.
56. Greco FA, Hainsworth JD. Prolonged administration of low-daily-dose etoposide: a superior dosing schedule? Cancer Chemother Pharmacol 1994;34(Suppl):S101-S104.
57. Hainsworth JD. Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma. Leuk Lymphoma 1993;10(Suppl):65-72.
58. Hainsworth JD, Johnson DH, Frazier SR et al. Chronic daily administration of oral etoposide-a phase I trial. J Clin Oncol 1989;7:396-401.
59. Hainsworth JD, Johnson DH, Frazier SR et al. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990;26:818-821.
60. Hainsworth JD, Johnson DH, Greco FA. Chronic etoposide schedules in the treatment of non-Hodgkin's lymphoma. Semin Oncol 1992;19:13-18.
61. Hainsworth JD. Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues. Drugs 1999;58 (Suppl 3):51-56.
62. Hande KR, Krozely MG, Greco FA et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11:374-377.
63. Itoh K, Shimada T, Horibe T et al. Waldenstrom's macroglobulinemia effectively treated with chronic daily oral administration of low-dose etoposide. Gan To Kagaku Ryoho 1998;25:2131-2134.
64. Kato Y, Takeda H, Mihara H et al. Oral low-dose etoposide therapy for refractory multiple myeloma with extramedullary involvement. Intern Med 1995;34:1023-1026.
65. Kojima H, Hori M, Shibuya A et al. Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction method. Cancer 1993;72:3614-3617.
66. Kuga T, Kohda K, Matsumoto S et al. Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies. Gan To Kagaku Ryoho 1997;24:315-321.
67. Kura Y, Sawada U, Yamazaki T et al. Daily oral low dose etoposide therapy for patients with relapsed or resistance non-Hodgkin's lymphoma (NHL) [abstract]. Proc ASCO 2000;19:25a
68. Mantadakis E, Herrera L, Leavey PJ et al. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. J Clin Oncol 2000;18:2576-2581.
69. Matsushita K, Matsumoto T, Ohtsubo H et al. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma 1999;36:67-75.
70. Niitsu N, Umeda M. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. Am J Clin Oncol 1997;20:311-314.
71. Sakoda H, Yoshida H, Usami M et al. Chronic daily oral low-dose etoposide therapy for an aged patient with aggressive lymphoma: a successful case report. Gan To Kagaku Ryoho 1993;20:1079-1082.
72. Sessa C, Zucchetti M, Cerny T et al. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 1995;13:200-209.
73. Seymour MT, Mansi JL, Gallagher CJ et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-195.
74. Slevin ML. Low-dose oral etoposide: a new role for an old drug? J Clin Oncol 1990;8:1607-1609.
75. Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 1998;16:333-335.
76. Waits TM, Johnson DH, Hainsworth JD et al. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol 1992;10:292-296.
77. Yasumizu T, Kato J. Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus. J Obstet Gynaecol 1995;21:569-576.
78. Zucchetti M, Pagani O, Torri V et al. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. Clin Cancer Res 1995;1:1517-1524.
79. Asou N, Suzushima H, Nishimura S et al. Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide. Am J Hematol 2000;63:35-37.
80. Glode LM, Crighton F, Johnson A et al. Metronomic therapy with low dose cyclophosphamide (CY) and dexamethasone (DEX) for prostate cancer [abstract]. Proc ASCO 2001;20:161b.
81. Brandes LJ, Israels LG. Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone. Cancer Treat Rep 1982;66:1413-1415.
82. Brandes LJ, Israels LG. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987;39:362-368.
83. Guthrie D. The treatment of advanced cystadenocarcinoma of the ovary with gestronol and continuous oral cyclophosphamide. Br J Obstet Gynaecol 1979;86:497-500.
84. Leonard RC, Cameron DA, Anderson A et al. Idarubicin and cyclophosphamide-an active oral chemotherapy regimen for advanced breast cancer. Crit Rev Oncol Hematol 2000;33:61-66.
85. Raghavan D, Cox K, Pearson BS et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993;72:625-628.
86. Colleoni M, Rocca A, Sandri MT et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, in press.
87. Dowell JE, Sinard R, Yardley DA et al. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol 1999;9:97-101.
88. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-192.
89. Rosenthal DI, Okani O, Truelson JM et al. Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies. Semin Oncol 1997;24:S2.
90. Rosenthal DI, Close LG, Lucci JA III et al. Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors. Semin Oncol 1995;22:13-17.
91. Rosenthal DI, Lee JH, Sinard R et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001;19:1363-1373.
92. Rosenthal DI, Okani O, Corak J et al. Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study. Semin Oncol 1997;24:S12.
93. Rosenthal DI, Sinard RJ, Okani O et al. Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study. Semin Oncol 1997;24:S19.
94. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
95. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999;26:28-31.
96. Hainsworth JD, Burris HA, Greco FA. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol 1999;26:19-24.
97. Briasoulis E, Karavasilis V, Anastasopoulos D et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999;10:701-706.
98. Kobayashi A, Yamaguchi M. Effect of combination chemotherapy of low-dose CDDE Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis. Gan To Kagaku Ryoho 1998;25:1755-1759.
99. Sasaki K, Takasaka H, Kawasaki H et al. Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis. Gan To Kagaku Ryoho 2000;27:915-919.
100. Takahashi Y, Mai M. Chemotherapy by combination of low-dose CPT-11 and PSK in an elderly man with liver metastasis from gastric cancer. Gan To Kagaku Ryoho 2001;28:531-534.
101. Takahashi Y, Omote K, Kitagata S et al. Low-dose CPT-11 against a recurrent rectal cancer-a case report. Gan To Kagaku Ryoho 1999;26:1193-1196.
102. Takahashi Y, Kitagata S, Mai M. Weekly chemotherapy with alternating low-dose CPT-11 and low-dose FP against a far advanced pancreatic cancer-a case report. Gan To Kagaku Ryoho 2000;27:1581-1584.
103. Baker SD, Diasio RB, O'Reilly S et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 2000;18:915-926.
104. Mani S, Hochster H, Beck T et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2000;18:2894-2901.
105. Smith IE, Johnston SR, O'Brien ME et al. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. J Clin Oncol 2000;18:2378-2384.
106. Chung YS, Yamashita Y, Inoue T et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997;80:1-7.
107. Kamata T, Morita A, Nakamoto A et al. Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma. Gan To Kagaku Ryoho 2000;27:859-864.
108. Kikuchi H, Ujiie S, Kanamaru R. Advanced pancreatic cancer successfully treated with continuous infusion of 5-fluorouracil and low-dose cisplatin. Intern Med 1998;37:635-637.
109. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:3537-3541.
110. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:301-308.
111. Toffoli G, Sorio R, Aita P et al. Pharmacology of chronic oral daily administration of idarubicin. Haematologica 1997;82:1-3.
112. Seidman AD, Hochhauser D, Gollub M et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-1884.
113. Gratton JP, Morales-Ruiz M, Kureishi Y et al. Akt down regulation of p38 signaling provides a novel mechanism of VEGF mediated cytoprotection in endothelial cells. J Biol Chem 2001; in press.
114. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol (Cell Physiol) 2001;280:C1375-C1386.
115. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 2000;97:12782-12787.
116. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 2000;9:1383-1396.
117. Park JS, Qiao L, Su ZZ et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 2001;20:3266-3280.
118. Geng L, Donnelly E, McMahon G et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-2419.
119. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-3378.
120. Maniwa Y, Okada M, Ishii N et al. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114:1668-1675.
121. Weitman SD, Glatstein E, Kamen BA. Back to the basics: the importance of concentration × time in oncology. J Clin Oncol 1993;11:820-821.
122. Shimoyama M. The cytocidal action of alkylating agents and anticancer antibiotics against in vitro cultured Yoshida ascites sarcoma cells. Nippon Gan Chiryo Gakkai Shi 1975;10:63-72.
123. Shimoyama M. Cytocidal action of anticancer antigens: evaluation of the sensitivity of cultured animal and human cancer cells. Bibl Haematol 1975;40:711-722.
124. Chresta CM, Hicks R, Hartley JA et al. Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine. Cancer Chemother Pharmacol 1992;31:139-145.
125. Lorico A, Boiocchi M, Rappa G et al. Increase in topoisomerase-II- mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate. Int J Cancer 1990;45:156-162.
126. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988;121-141.
127. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24:S10.
128. Murray N, Livingston RB, Shepherd FA et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308.
129. Fidler IJ, Ellis LM. Chemotherapeutic drugs-more really is not better. Nat Med 2000;6:500-502.
130. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
131. Kamen BA, Drachtman R. "To the heart of the matter...." Pediatr Hematol Oncol 2000;17:5-7.
132. Takahashi Y, Mai M, Taguchi T et al. Prolonged stable disease effects survival in patients with solid gastric tumor: analysis of phase II studies of doxifluridine. Int J Oncol 2000;17:285-289.
133. Takahashi Y, Nishioka K. Survival without tumor shrinkage: reevaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 1995;87:1262-1263.
134. Shalinsky DR, Brekken J, Zou H et al. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest New Drugs 1998;16:303-313.
135. Kollum M, Cottin Y, Chan RC et al. Delayed re-endothelialization and T-cell infiltration following intracoronary radiation therapy in the porcine model. Int J Radiat Oncol Biol Phys 2001;50:495-501.
136. 32)P beta-emitting stent placement. Int J Radiat Oncol Biol Phys 2000;48:889-898.
137. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000;5 (Suppl 1):20-27.
138. Bengtson EM, Rigas JR. New oral chemotherapeutic agents for lung cancer. Drugs 1999;58 (Suppl 3):57-69.
139. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-2567.
140. Diasio RB. Current status of oral chemotherapy for colorectal cancer. Oncology 2001;15:16-20.
141. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
142. Lament EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 1999;5:2289-2296.
143. Ajani JA, Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs 1999;58 (Suppl 3):85-90.
144. Treat J, Damjanov N, Huang, C et al. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology 2001;15:44-48.
145. Cabanes A, Briggs KE, Gokhale PC et al. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 1998;12:1035-1040.
146. Ratain MJ, Schilsky RL, Conley BA et al. Pharmacodynamics in cancer therapy. J Clin Oncol 1990;8:1739-1753.
147. Harris AL, Reusch P, Barleon B et al. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001;7:1992-1997.
148. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491.
149. Evans WE, Relling MV, Rodman JH et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.
150. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
151. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19-27.
152. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
153. McCarty MF. Current prospects for controlling cancer growth with non-cytotoxic agents-nutrients, phytochemicals, herbal extracts, and available drugs. Med Hypotheses 2001;56:137-154.
154. Murata T, He S, Hangai M et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:2309-2317.
155. Yamakawa K, Hosoi M, Koyama H et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;271:571-574.
156. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999;274:17042-17048.
157. Xin X, Yang S, Kowalski J et al. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-9121.
158. Marson LP, Kurian KM, Miller WR et al. The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res Treat 2001;66:9-15.
159. Blackwell KL, Haroon ZA, Shan S et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 2000;6:4359-4364.
160. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993;53:533-535.
161. Bouck N, Campbell S. Anti-cancer dividends from captopril and other inhibitors of angiogenesis. J Nephrol 1998;11:3-4.
162. Vogt B, Frey FJ. Inhibition of angiogenesis in Kaposi's sarcoma by captopril. Lancet 1997;349:1148.
163. Volpert OV, Ward WF, Lingen MW et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-679.
164. Brem S. Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control 1999;6:436-458.
165. Brem SS, Zagzag D, Tsanaclis AM et al. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990;137:1121-1142.
166. Matsubara T, Saura R, Hirohata K et al. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest 1989;83:158-167.
167. Cai T, Fassina G, Morini M et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest 1999;79:1151-1159.
168. Morini M, Cai T, Aluigi MG et al. The role of the thiol N-acetylcysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 1999;14:268-271.
169. Gross J, Azizkhan RG, Biswas C et al. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci USA 1981;78:1176-1180.
170. Yamamoto T, Terada N, Nishizawa Y et al. Angiostatic activities of medroxyprogesterone acetate and its analogues. Int J Cancer 1994;56:393-399.
171. Ozawa S, Shinohara H, Kanayama H et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001;3:154-164.
172. Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behcet's disease. Br J Ophthalmol 2000;84:1437-1438.
173. Slaton JW, Perrotte P, Inoue K et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-2734.
174. Dinney CP, Bielenberg DR, Perrotte P et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-814.
175. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.
176. Nagashima M, Yoshino S, Aono H et al. Inhibitory effects of antirheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol 1999;116:360-365.
177. Koch AE, Burrows JC, Polverini PJ et al. Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity. Agents Actions 1991;34:350-357.
178. Hermans P, Clumeck N, Picard O et al. AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. J Hum Virol 1998;1:82-89.
179. Gill PS, McLaughlin T, Espina BM et al. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma. J Natl Cancer Inst 1997;89:1797-1802.
180. Gill PS, Lunardi-Ishkandar Y, Louie S et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996;335:1261-1269.
181. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93-105.
182. Collen A, Smorenburg SM, Peters E et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000;60:6196-6200.
183. Zacharski LR, Ornstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000;26 (Suppl 1):69-77.
184. Norrby K, Ostergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis. Int J Microcirc Clin Exp 1997;17:314-321.
185. Norrby K, Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 1996;16:8-15.
186. Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically Haemostasis 1993;23(Suppl):141-149.